A Stanford University study reveals that a low dose of the opioid antagonist naltrexone significantly reduces daily pain in patients with fibromyalgia, according to a Medscape News report.
The findings, first reported at the American Academy of Pain Medicine’s annual meeting, suggest that a unique microglial target can effectively treat the disorder, according to lead investigator Jarred Younger, PhD.
Despite the study’s promising data, the low-dose amount of naltrexone used on participants is not yet commercially available and must be compounded manually for patients.
Study: Risk of Perioperative Infection Lower in Patients With Chronic Opioid Consumption
Ameritox Supports New Recommendations for Long-Term Opioid Therapy
The findings, first reported at the American Academy of Pain Medicine’s annual meeting, suggest that a unique microglial target can effectively treat the disorder, according to lead investigator Jarred Younger, PhD.
Despite the study’s promising data, the low-dose amount of naltrexone used on participants is not yet commercially available and must be compounded manually for patients.
Related Articles on Pain Management:
Florida Pain Network Adds Orlando Clinics to Expanded DatabaseStudy: Risk of Perioperative Infection Lower in Patients With Chronic Opioid Consumption
Ameritox Supports New Recommendations for Long-Term Opioid Therapy